Manchester University NHS Foundation Trust (MFT) has been named as one of a very small number of centres in the UK to offer a revolutionary new cancer treatment, widely regarded as the most exciting cancer treatment development in decades.
MFT will be able to offer the ground-breaking treatment to children and adults and is unique in this regard. Within MFT, the treatment will be delivered in Royal Manchester Children’s Hospital and Manchester Royal Infirmary.
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a personalised medicine used to treat patients with certain types of leukaemia and lymphoma.
It is a highly complex new type of immunotherapy which involves collecting and using the patients’ own immune cells to target their cancer in a process which is completed over a number of weeks.
Sir Michael Deegan CBE, Chief Executive of MFT, said; “This new personalised therapy will deliver huge benefits to cancer patients and we are very proud to be leading the way nationally at MFT by being able to offer this revolutionary CAR-T treatment for both children and adults at the Royal Manchester Children’s Hospital and Manchester Royal Infirmary. This is a significant advancement in the treatment of cancer, offering new hope to patients when other treatment options have failed.”
